drugset / Trial / NCT05148533
A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
This study is a phase I/II study of single drug TJ011133 and Toripalimab combine treatment forAdvanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension. The purpose of part A is to comfirm the MTD or MED and the clinical dose. The purpose of part B is to observe the safty, effectiveness, PK, PD and biomarker properties for effective subjects.
Timeline
- Start
- 2021-12-30
- Primary completion
- 2023-02-03
- Completion
- 2023-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lemzoparlimab | Monoclonal antibody | 30 mg/kg | — |
| Subject | Lemzoparlimab | Monoclonal antibody | 45 mg/kg | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |